In the general population, dyslipidaemia and abdominal obesity are risk factors for cardiovascular disease, but less is known about their roles in patients on maintenance haemodialysis (HD). This study investigated the association between blood lipids and abdominal obesity, as determined by waist circumference (WAC), and body mass index (BMI) in 72 HD patients (32 women). Blood lipid levels were measured using routine laboratory methods. Abdominal obesity, based on the WAC measurement, was found in 62.5% of HD patients (75.0% of women; 52.5% of men). Triglyceride levels were higher in abdominally obese compared with abdominally non-obese men. According to BMI measurements, 34.7% of HD patients were overweight/obese and 9.7% were underweight. In men, WAC and BMI were positively correlated with triglyceride levels. In women, WAC was negatively correlated with high-density lipoprotein (HDL) cholesterol and apolipoprotein A levels. The results indicated that there was a negative association of abdominal obesity and BMI with HDL cholesterol in HD patients.
KeuczmarskiRJFlegalKMCampbellSM: Increasing prevalence of overweight among US adults. The National Health and Examination Surveys, 1960 to 1991. JAMA1994; 272: 205–211.
2.
Lev-RanA: Human obesity: an evolutionary approach to understanding our bulging waistline. Diabetes Metab Res Rev2001; 17: 347–362.
3.
ByersT: Body weight and mortality. N Eng J Med1995; 333: 723–724.
4.
MansonJEWillettWCStampferMJ: Body weight and mortality among women. N Engl J Med1995; 333: 677–685.
5.
LewEAGarfinkelL: Variations in mortality by weight among 750,000 men and women. J Chronic Dis1979; 32: 563–576.
6.
CoreshJAstorBCGreeneT: Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis2003; 41: 1–12.
7.
KoppleJD: Nutritional status as a predictor of morbidity and mortality in maintenance dialysis patients. ASAIO J1997; 43: 246–250.
8.
Kalantar-ZadehKKilpatrickRDKoppleJD: A matched comparison of serum lipids between hemodialysis patients and nondialysis morbid controls. Hemodial Int2005; 9: 314–324.
9.
FleischmannETealNDudleyJ: Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. Kidney Int1999; 55: 1560–1567.
10.
Kalantar-ZadehKAbbottKCSalahudeenAK: Survival advantages of obesity in dialysis patients. Am J Clin Nutr2005; 81: 543–554.
11.
Kalantar-ZadehKKoppleJDKilpatrickRD: Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis2005; 46: 489–500.
12.
JandacekRJAndersonNLiuM: Effects of yo-yo diet, caloric restriction, and olestra on tissue distribution of hexachlorobenzene. Am J Physiol Gastrointest Liver Physiol2005; 228: G292–G299.
13.
ImbeaultPTremblayASimoneauJA: Weight loss-induced rise in plasma pollutant is associated with reduced skeletal muscle oxidative capacity. Am J Physiol Endocrinol Metab2002; 282: E574–E579.
14.
HorwichTBFonarowGCHamiltonMA: The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol2004; 38: 789–795.
15.
SchrierRWAbrahamWT: Hormones and hemodynamics in heart failure. N Engl J Med1999; 341: 577–585.
16.
AvramMMGoldwasserPBurrellDE: The uremic dyslipidemia: A cross-sectional and longitudinal study. Am J Kidney Dis1992; 20: 324–335.
17.
ShojiTIshimuraEInabaM: Atherogenic lipoproteins in end-stage renal disease. Am J Kidney Dis2001; 38 (4 suppl 1): S30–S33.
18.
CoreshJLongeneckerJCMillerER3rd: Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol1998; 9 (12 suppl): S24–S30.
19.
FoleyRNParfreyPSSarnakMJ: Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis1998; 32 (5 suppl 3): S112–S119.
20.
EkartRHojsRHojs-FabjanT: Cardiovascular diseases and chronic renal failure. Zdrav vestin2003; 72: 145–152 [in Sloveniain, English abstract].
21.
KoppleJDZhuXLewNL: Body weight-for-height relationships predict mortality in maintenance hemodialysis patients. Kidney Int1999; 56: 1136–1148.
22.
Kalantar-ZadehKKilpatrickRDMcAllisterCJ: Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th Annual Fall Conference and Scientific Sessions. Hypertension2005; 45: 811–817.
23.
NishizawaYShojiTIshimuraE: Paradox of risk factors for cardiovascular mortality in uraemia: is a higher cholesterol level better for atherosclerosis in uraemia?Am J Kidney Dis2001; 38 (4 suppl 1): S4–S7.
24.
Kalantar-ZadehKBlockGHumphreysMH: A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol2004; 15: 442–453.
25.
LowrieEGLewNL: Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis1990; 15: 458–482.
26.
Kalantar-ZadehKBlockGHumphreysMH: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int2003; 63: 793–808.
27.
KoppleJD: The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr2005; 81: 1257–1266.
28.
Kalantar-ZadehK: What is so bad about reverse epidemiology anyway?Semin Dial2007; 20: 593–601.
29.
NiebauerJVolkHDKempM: Endotoxin and immune activation in chronic heart failure: A prospective cohort study. Lancet1999; 353: 1838–1842.
30.
RauchhausMCoatsAJAnkerSD: The endotoxin—lipoprotein hypothesis. Lancet2000; 356: 930–933.
31.
AlbertiKGMMZimmetPShawJ: Metabolic syndrome—a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med2006; 23: 469–480.
32.
ChanDTIrishABDograGK: Dyslipidemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials. Atherosclerosis2008; 196: 823–834.
33.
KimakESolskiJ: ApoA- and apoB-containing lipoproteins and Lp(a) concentration in non-dialyzed patients with chronic renal failure. Ren Fail2002; 24: 485–492.
34.
AmannK: Media calcification and intima calcification are distinct entities in chronic kidney disease. Clin J Am Soc Nephrol2008; 3: 1599–1605.
35.
VaziriND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol2006; 290: F262–F272.
36.
FreedmanDSJacobsenSJBarboriakJJ: Body fat distribution and male/female differences in lipids and lipoproteins. Circulation1990; 81: 1498–1506.
37.
MaksvytisAStakišaitisD: Impact of obesity on lipid profiles in middle-aged women. Medicina (Kaunas)2004; 40: 553–557.
LeePO'NealDMurphyB: The role of abdominal adiposity and insulin resistance in dyslipidemia of chronic renal failure. Am J Kidney Dis1997; 1: 54–65.
40.
SemposCTCleemanJICarrollMD: Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. JAMA1993: 269: 3009–3014.
41.
KaizuYTsunegaYYoneyamaT: Overweight as another nutritional risk factor for the long-term survival of non-diabetic hemodialysis patients. Clin Nephrol1998; 50: 44–50.
42.
KimCVaziriND: Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int2005; 67: 1028–1032.
43.
OzturkICKilleenAA: An overview of genetic factors influencing plasma lipid levels and coronary artery disease risk. Arch Pathol Lab Med1999; 123: 1219–1222.
